Fujian Haixi Pharmaceuticals Co., Ltd. (HAIXI PHARMA) published its 2025 Environmental, Social and Governance Report covering operations from 1 January 2025 to 31 December 2025. The disclosure follows the Hong Kong Stock Exchange ESG Reporting Code and centres on four pillars: Innovative Pharmaceuticals, Green System, People Centricity and Returns to Society. Key data and targets are as follows:
• Carbon-reduction roadmap – The group pledges to lower Scope 1 & 2 greenhouse-gas intensity (tCO₂e per RMB 0.01 billion revenue) and electricity-consumption intensity by 5% from the 2024 base year by 2030. 2025 emissions totalled 4,475.60 tCO₂e for Scope 1 & 2 and 29,246.15 tCO₂e including Scope 3, translating into 0.077 tCO₂e and 0.50 tCO₂e per RMB 0.01 billion revenue respectively.
• Energy and renewables – Total energy use reached 10,455.51 MWh; a 1.7 MWp rooftop solar project is installed and scheduled to begin generation in early 2026.
• Waste management – 25.81 tonnes of hazardous and 21.00 tonnes of non-hazardous waste were generated, equal to 0.44 kg and 0.36 kg per RMB 0.01 billion revenue. All hazardous waste was handled by licensed contractors; no environmental non-compliance incidents were recorded.
• Water stewardship – Consumption stood at 55,767 m³, or 0.96 m³ per RMB 0.01 billion revenue. The company targets a 5% intensity reduction from 2024 by 2030.
• Product portfolio – Marketing approval has been obtained for 15 pharmaceuticals; R&D pipeline includes four innovative drug candidates such as C019199 (multi-mechanism immunomodulator) and HXP056 (oral therapy for retinal diseases). Over 39 invention patents are in force globally.
• Quality and safety – No product recalls, material customer complaints or adverse regulatory findings occurred in 2025. A 24-hour feedback mechanism delivered a 100% on-time issue-confirmation rate.
• Workforce – Headcount totalled 200 (49.5% male, 50.5% female). Employee turnover was 17.5%; no work-related fatalities or injuries were reported, meeting the “zero major safety accident” target. Average training hours per employee reached 0.78.
• Governance – The board retains ultimate ESG oversight with an ESG Working Group reporting at least annually. No corruption, fraud or bribery cases were concluded against the company or staff during the period.
• Supply chain – 135 suppliers (106 mainland China, 29 overseas) are subject to a Supplier Code of Conduct covering environment, labour and ethics.
• Community and access – HAIXI PHARMA collaborates with Peking University, Xiamen University and local institutions to expand affordable medicine availability and serves as an internship base for regional universities.
Management reiterated the strategic theme “Generics Empower Innovation, Innovation Drives the Future” and confirmed that the company remains on track to meet its 2030 environmental intensity targets while pursuing pipeline expansion and continued compliance across operational, social and governance dimensions.
Comments